

Volume 25

Supplement 1

July 1997

Clinical Infectious Diseases

AN OFFICIAL PUBLICATION OF THE INFECTIOUS DISEASES SOCIETY OF AMERICA

PUBLISHED BY
THE UNIVERSITY OF
CHICAGO PRESS

**Basic and Clinical Approaches to Lyme Disease: A Lyme Disease
Foundation Symposium**

Boston, Massachusetts
19-20 April 1997

Guest Editor: Edward Bosler

Associate Editors: Elizabeth Aberer
Sam Donta

Publication of this supplement was made possible by a grant from the Demarest family.

The meeting was sponsored by the Lyme Disease Foundation.

A major grant for the symposium was provided by Connaught Laboratories.

The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or to the publisher, editor, or editorial board of *Clinical Infectious Diseases*. References made in the articles may indicate uses of drugs or dosages for periods of time, in indications, or in combinations not included in the current prescribing information. The reader is therefore urged to check the full prescribing information for each drug for the recommended indications and dosage, as well as for added warnings and precautions, and to use clinical judgment in weighing the benefits of treatment against the risk of toxicity.

Clinical Infectious Diseases

Volume 25 • Supplement 1

July 1997

Basic and Clinical Approaches to Lyme Disease: A Lyme Disease Foundation Symposium

- 1.** S1 Introduction
Edward M. Bosler
- 2.** S2 Invasion and Cytopathic Killing of Human Lymphocytes by Spirochetes Causing Lyme Disease
David W. Dorward, Elizabeth R. Fischer, and Diane M. Brooks
- 3.** S9 Protective and Arthritis-Resolving Activity in Sera of Mice Infected with *Borrelia burgdorferi*
Stephen W. Barthold, Sunlian Feng, Linda K. Bockenstedt, Erol Fikrig, and Kevin Feen
- 4.** S18 Pathological Manifestations in Murine Lyme Disease: Association with Tissue Invasion and Spirochete Persistence
Janis J. Weis, Liming Yang, Kathleen Petri Seiler, and Robert M. Silver
- 5.** S25 Activity of Sera from Patients with Lyme Disease Against *Borrelia burgdorferi*
Charles S. Pavia, Gary P. Wormser, and Gary L. Norman
- 6.** S31 The Western Immunoblot for Lyme Disease: Determination of Sensitivity, Specificity, and Interpretive Criteria with Use of Commercially Available Performance Panels
Richard C. Tilton, Mary N. Sand, and Mark Manak
- 7.** S35 The Cold Zone: A Curious Convergence of Tick-Transmitted Diseases
David H. Persing
- 8.** S43 Is Human Granulocytic Ehrlichiosis a New Lyme Disease? Review and Comparison of Clinical, Laboratory, Epidemiological, and Some Biological Features
J. Stephen Dumler
- 9.** S48 The Antimicrobial Agent Melittin Exhibits Powerful In Vitro Inhibitory Effects on the Lyme Disease Spirochete
Lori L. Lubke and Claude F. Garon
- 10.** S52 Tetracycline Therapy for Chronic Lyme Disease
Sam T. Donta
- 11.** S57 Functional Brain Imaging and Neuropsychological Testing in Lyme Disease
Brian A. Fallon, Sam Das, Jeffrey J. Plutchok, Felice Tager, Kenneth Liegner, and Ronald Van Heertum
- 12.** S64 Why Is Chronic Lyme Borreliosis Chronic?
Elisabeth Aberer, Frieder Koszik, and Maria Silberer
- 13.** S71 Specific Issues in the Design and Implementation of an Efficacy Trial for a Lyme Disease Vaccine
François Meurice, Dennis Parenti, Darrick Fu, and David S. Krause